Survodutide
A dual GLP-1/glucagon receptor agonist in development for obesity that aims to reduce appetite and boost energy expenditure.
Plain English
Patient-Friendly Explanation
Survodutide is a new investigational weight loss medication that works on two hormone receptors at once — GLP-1 and glucagon — to help reduce appetite and increase the body's energy burning. It is given as a once-weekly injection and is being studied for both obesity and fatty liver disease.
Medical
Clinical Definition
Survodutide is a dual GLP-1/glucagon receptor agonist in phase 3 clinical development for obesity. Unlike pure GLP-1 agonists, the addition of glucagon receptor agonism is intended to increase energy expenditure through enhanced lipolysis and thermogenesis, complementing the appetite-suppressing and glycaemic effects of GLP-1 agonism.
Key Insight
Why It Matters
Medications that both suppress appetite AND increase calorie burning could offer more powerful weight loss than current options. Dr Joseph Wang monitors the clinical trial data on survodutide so Accord Medical patients can benefit from evidence-based treatment advances.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: August 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.